Targeted Therapy Effective Prior to Chemotherapy
Published: 2019-06-04 |
Source: MD Anderson Cancer Center
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for new diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).
The first-of-its-kind study examined a treatment regimen without chemotherapy for patients with non-germinal center (non-GCB) DLBCL, and while confirmatory trials are needed, the findings suggest that patients who respond to targeted therapy initially may not need chemotherapy, currently the standard care.
"The responses we've seen have been remarkable. More than 80 percent of our patients have responded and around 40 percent have a complete response, showing no evidence of cancer, prior to receiving any chemotherapy," said Westin. "All patients have gone on to receive standard chemotherapy in combination with these targeted treatments per the protocol, and so far, we've had a 100 percent response rate."